PRHSX - T. Rowe Price Health Sciences Fund

Nasdaq - Nasdaq Delayed Price. Currency in USD
+0.82 (+1.11%)
At close: 8:00PM EDT
Stock chart is not supported by your current browser
Previous Close73.76
YTD Return8.51%
Expense Ratio (net)0.77%
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingAbove Average
Sustainability Rating
Net Assets11.94B
Beta (3Y Monthly)1.15
5y Average ReturnN/A
Holdings Turnover43.00%
Last Dividend0.00
Average for CategoryN/A
Inception DateDec 29, 1995
  • 3 Mutual Fund Misfires to Avoid - September 27, 2019 (Revised)

    3 Mutual Fund Misfires to Avoid - September 27, 2019 (Revised)

    You may need to start looking for a new financial advisor if your current one has put any of these high-fee, low - return "Mutual Fund Misfires of the Market" into your portfolio.

  • 6 Best Health Care Funds for a Volatile Market

    6 Best Health Care Funds for a Volatile Market

    Let's face it: The stock market is infuriating. Valuations are high, global growth is slow, and President Donald Trump's trade war with China has brought elevated volatility to stocks. Meanwhile, bonds, the only sensible alternative, are at near-record high prices and thus offer puny yields.What's an investor to do? One partial remedy is to increase your investment in health care stocks.Health care, which comprises more than 15% of Standard & Poor's 500-stock index, is the only broad market sector that can hold its own in both bull and bear markets. Although, no question, its best performance relative to the overall stock market comes during selloffs. In 2018, for instance, while the S&P; 500 retreated by 4.6% on a total-return basis (price plus dividends), the health care sector gained 5.6%.Which would you rather have: a shiny new BMW or your health? To ask the question is to answer it. If you're really sick, you'll do whatever it takes to recover, no matter the cost. You'll skip the new car, if necessary. Demand for health care is virtually inelastic. What's more, as baby boomers age, they're requiring more medical care. Simultaneously, breakthrough advances in the treatments of diseases - often expensive treatment - continue at a rapid clip.Below are my six best health care funds, in no particular order. SEE ALSO: The 19 Best ETFs for a Prosperous 2019

  • 4 Healthcare Funds to Grab Today

    4 Healthcare Funds to Grab Today

    Below we share with you four top-ranked healthcare mutual funds. Each has earned a Zacks Mutual Fund Rank 1 (Strong Buy).

  • 4 Top Funds to Buy on a Hearty July Jobs Report

    4 Top Funds to Buy on a Hearty July Jobs Report

    Investors should consider professional services, healthcare and financial sectors for investments.

  • Which Healthcare Mutual Fund Should You Buy: FBIOX or PRHSX?

    Which Healthcare Mutual Fund Should You Buy: FBIOX or PRHSX?

    Often, the healthcare sector is relied on for safeguarding investments.

  • 4 Best-Performing Biotech Mutual Funds in 2019 So Far

    4 Best-Performing Biotech Mutual Funds in 2019 So Far

    After stumbling into the bear market territory in the second half of last year, the U.S. biotechnology sector recovered in the first six months of this year.

  • 4 Popular Healthcare Mutual Funds to Add to Your Portfolio

    4 Popular Healthcare Mutual Funds to Add to Your Portfolio

    Below we share with you four top-ranked healthcare mutual funds. Each has earned a Zacks Mutual Fund Rank 1 (Strong Buy)

  • 5 Top-of-the-Line T. Rowe Price Mutual Funds

    5 Top-of-the-Line T. Rowe Price Mutual Funds

    T. Rowe Price (TROW) employs more than 600 investment professionals who manage nearly $1.1 trillion for investors in 49 countries. But when you visit the Baltimore headquarters, you still get a feel of the firm as a small, collegial group that enjoys working together.The secret to T. Rowe Price's success, in my view, is its sterling corporate culture. This is a company with character. The average investment pro has 22 years of experience; many remain with T. Rowe for their entire careers. All this - plus the products' above-average long-term returns and below-average expense ratios - makes T. Rowe mutual funds a good choice for investors.The firm was launched in 1937 by Thomas Rowe Price Jr., who had a novel idea (at the time) that buying growth stocks - those with rising earnings and revenues - could be just as successful as value investing, which was ascendant during the Great Depression that followed the 1929 stock market crash.The theory was sound, but the timing was awful. The T. Rowe Price investment firm didn't turn a profit until 1950 - the same year that it launched its first mutual fund, T. Rowe Price Growth Stock (PRGFX). The firm subsequently broadened its scope to include value stocks, foreign stocks and small-cap stocks, as well as bond funds. Since then, it has done quite well indeed.Do you think index funds are the only way to invest? T. Rowe begs to differ. Indeed, 79% of its U.S. equity funds beat their benchmark over the past 10 years.But which are the best T. Rowe Price mutual funds on offer? Here are my thoughts. SEE ALSO: The 27 Best Mutual Funds in 401(k) Retirement Plans

  • 4 T. Rowe Price Mutual Funds for a Healthy Portfolio

    4 T. Rowe Price Mutual Funds for a Healthy Portfolio

    Below we share with you four top-ranked T. Rowe Price mutual funds. Each has earned a Zacks Mutual Fund Rank 1 (Strong Buy).

  • 3 T. Rowe Price Mutual Funds to Buy Today

    3 T. Rowe Price Mutual Funds to Buy Today

    Below we share with you three top-ranked T. Rowe Price mutual funds. Each has earned a Zacks Mutual Fund Rank 1 (Strong Buy)

  • 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund

    7 Stocks to Buy From the T. Rowe Price Health Sciences Fund

    Want to make money on the stock market? One of the best ways to find good healthcare stocks to buy is by following the best ideas of successful portfolio managers. How do you find them? Well, you could use a mutual fund screener to find top performers. Or, you could do a Google search for mutual funds that gained notoriety in 2018 and buy the fund manager's best ideas. I'm talking about stocks in the top 10 or top 25 holdings. InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe only problem with this solution is that mutual fund holdings aren't real time, so you're usually getting a list of stocks that are stale, dated, and no longer at the top of the fund manager's holdings list or even a holding 4-6 weeks after the end of the quarterly report. This little problem aside, it's still an excellent way to get ideas, even if you ultimately don't pull the trigger. And two of the best-performing categories of mutual funds in 2018 were large-cap growth and healthcare funds. One of these healthcare funds was the T. Rowe Price Health Sciences Fund (MUTF:PRHSX), which had a total return of 1.23% last year, 561 basis points higher than the S&P 500. * 7 Energy Stocks to Buy to Light Up Your Portfolio Trailing the index by a significant amount through the first four months now might be the perfect time to check out its holdings list for healthcare stocks to buy. Healthcare Stocks to Buy: United Health (UNH)Source: Shutterstock UnitedHealth Group (NYSE:UNH) is the fund's number one holding with a weighting of 6.5% as of March 31. For obvious reasons which I'll explain, UNH stock hasn't had a good year to date. It's down over 6%, well behind the 17.5% gain by the S&P 500. UnitedHealth has two distinct businesses: The first provides healthcare plans for a company's employees. That's UnitedHealth. The second, known as Optum, provides health services to individuals, many of them having UnitedHealth healthcare benefits. As the Democratic candidates have come out of the woodwork in 2019, many of them have called for some form of universal healthcare in the U.S., some even suggesting following a single-payer system like the kind found in Canada. The idea of implementing a socialist healthcare plan scared investors. As they wondered whether an entire half of UnitedHealth's business would be wiped out under such a scenario, UNH stock's become kryptonite. However, as I stated in my April 18 article about UNH, investors should consider buying its stock near 52-week lows because investor fears are likely overblown. Since then, it's up 6% through May 1. As healthcare stocks go, UNH is as stable as they come. Intuitive Surgical (ISRG)Source: Jon Fingas via Flickr (Modified)Of all the healthcare stocks in the fund's top 25 holdings, Intuitive Surgical (NASDAQ:ISRG) is probably the healthcare stock I'm most familiar. The second-largest holding in PRHSX, it has a weighting of 5.5%. Like UNH, ISRG hasn't exactly lit up the scoreboard in 2019. It's up 6% year to date. I first recommended ISRG stock in March 2013. Intuitive Surgical's stock price was under pressure due to lawsuits it faced over the company's da Vinci surgical systems. It got so severe that the FDA was looking into whether robotics was a threat to patient safety. As a result, ISRG was down 8.4% over 52 weeks, while the S&P 500 was up 25%, putting shareholders in a very grumpy mood. Here's what I said about its stock at that time:"Intuitive Surgical is a great company that is growing free cash flow at a significant rate. If you own shares already, I'd applaud any pullbacks in its stock. If you don't own any shares, buy some now and then some later if it drops some more. If you don't, you'll be kicking yourself in five years when it's a $1,000 stock." * 10 Cheap Stocks to Buy Now Well, hyperbole aside, it's still an outstanding healthcare stock to own, even at half the price. Pfizer (PFE)Source: Shutterstock I don't know which type of healthcare stock I have a harder time assessing: a big pharma play like Pfizer (NYSE:PFE) or a small biotech stock like Mustang Bio (NASDAQ:BIO). Not being a science guy, the jargon gets a bit tricky. The seventh-largest holding in the fund with a weighting of 2.9%, I picked Pfizer because it's recently added 1.2 million shares, increasing its shareholdings by 16%, the largest addition by shares in the top 25. Clearly, portfolio manager Ziad Bakri sees some serious capital appreciation in its future. I know InvestorPlace's own James Brumley thinks highly of Pfizer's drug pipeline. "Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full," Brumley wrote in April. "Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize."Translation: Pfizer should not be in negative territory given the strength of its portfolio of drugs combined with the momentum in the overall markets. At a 14x price-to-earnings ratio, it's trading at a valuation well below its historical norm. Roche (RHHBY)Source: Images Money via FlickrOf all seven of these healthcare stocks to buy, Roche (OTCMKTS:RHHBY) appears to be the only new position in the fund's top 25 holdings with an initial 664,009 shares bought. Why did Bakri buy into the Swiss pharmaceutical company? That I couldn't tell you. What I do know is that the company is optimistic about 2019. On April 17, Roche upped its outlook for the year due to higher sales expectations in both China and the U.S. This despite downward pricing pressure from President Trump. At the end of 2018, Roche projected its sales growth this year would be low-to-mid-single digits. In its Q1 2019 earnings release April 17, it said it now expects sales to grow by at least mid-single digits with core earnings rising by a similar amount. "We haven't taken any price increases in the U.S. since July 1," Bill Anderson, head of the Roche's drugs division, said on its conference call. "Overall in the world, our 10 percent sales growth in pharma was based on 15 percent volume growth and 5 percent average price declines across the portfolio." * The 10 Best Stocks to Buy for May Thanks to the company's newer cancer drugs like Tecentriq, it continues to deliver growth for shareholders. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Although Vertex Pharmaceuticals (NASDAQ:VRTX) is best known for its cystic fibrosis drugs Kalydeco, Orkambi, and Symdeko, with 37,000 patients currently eligible to use them, it's also focusing on transformative medicines beyond cystic fibrosis for kidney disease, neuropathic pain and others. Of the 37,000 potential patients, about half are receiving treatment at the moment. By treating younger patients, it hopes to get that number up to 44,000, and using a triple combination regimen, it has its sight on 68,000 patients worldwide. Accomplishing this goal takes cash flow. To that end, Vertex has grown its operating cash flow over the past three years by 448% to $1.27 billion. That's starting from -$365 million in operating cash flow at the end of 2015. As a result, it's added $2.2 billion in cash to its balance sheet. From negative cash flow just three years ago, its free cash flow is now higher than $1.1 billion. In the first quarter ended March 31, Vertex increased free cash flow by 38% year over year to $307 million. Up just 8% year to date, the next eight months look ready to deliver a higher share price. Thermo Fisher Scientific (TMO)Source: Shutterstock Of the top ten holdings in PRHSX, Thermo Fisher Scientific (NYSE:TMO) has the second-best total return year to date, up 24%. Only Sage Therapeutics (NASDAQ:SAGE) has a better return. The fifth-largest holding in the fund portfolio, Thermo Fisher Scientific is a big buyer of its stock. Last September it announced a $2 billion share repurchase program. On May 2, it announced its first-quarter earnings report. While the 10-Q's not out yet, it did say it repurchased $750 million of its stock during the first quarter ended March 30 and increased its quarterly dividend by 12%. InvestorPlace contributor Josh Enomoto summed up why TMO is such a great stock."If you think about it, Thermo Fisher stands on an almost unassailable position. The biotech sector will never stop searching for the next big therapy," Josh stated last September while discussing the company's big buyback. "Of course, not all contenders are successful. But TMO doesn't have to be: they provide the equipment necessary for other companies to do their work." * 7 Stocks That Are Soaring This Earnings Season Why try to pick the next great biotech stock when you can own TMO and win no matter who it turns out to be? HCA Healthcare (HCA)Source: Shutterstock Not a large holding in T. Rowe Price's health sciences fund at a weighting of 1.9% (16th position), HCA Healthcare (NYSE:HCA) was first bought in 2011, so it's one of the fund's long-time holdings. HCA stock took a beating in April due to the Medicare-for-All scare that hurt many of the big healthcare stocks. It dropped 10%, its worst single-day performance since Trump's election victory in November 2016. However, the owner of 185 hospitals and 119 freestanding surgery centers in 21 states, has seen its stock recover most of those losses over the subsequent 7-10 days. "The market is ascribing an inordinately high probability that some form of Medicare-for-All proposal could become reality," Cowen analyst Charles Rhyee wrote in a note in April. "In our view, Medicare-for-All fails the Occam's razor test."For those who aren't Latin scholars, it means other, more straightforward options will likely be used to reform the healthcare system.Americans, especially Republican politicians, are so afraid of socialism, there's no way Medicare-for-All gets passed into legislation. As the population continues to age, hospitals will continue to experience significant demand, making HCA an excellent long-term buy. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks to Buy to Light Up Your Portfolio * 10 Vice Stocks to Spice Up Your Portfolio * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund appeared first on InvestorPlace.

  • Health Care Stocks: Buy Them While They're Down

    Health Care Stocks: Buy Them While They're Down

    Why this sector should outperform for years to come

  • 4 Best Biotech Funds to Buy in Q2

    4 Best Biotech Funds to Buy in Q2

    The biotechnology sector fared well in Q1 and is expected to continue doing so through Q2 on the back of a few encouraging trends.

  • 3 Mutual Funds to Gain From Strength in U.S. Healthcare

    3 Mutual Funds to Gain From Strength in U.S. Healthcare

    Despite price hearing woes, drug stocks are poised to get a boost in 2019 on a judicious drug pricing model.

  • 3 Top Health Care Mutual Funds for 2019

    3 Top Health Care Mutual Funds for 2019

    Implementation of artificial intelligence along with other technological advancements in health care could remarkably increase the sector???s proficiency.

  • 4 Best Performing Mutual Funds of 2018

    4 Best Performing Mutual Funds of 2018

    Historically, when markets turn jittery, large-cap growth stocks outperform small-caps as well as mid-cap ones.

  • 3 Healthcare Mutual Funds to Buy for 2019

    3 Healthcare Mutual Funds to Buy for 2019

    U.S. healthcare sector is poised for good growth ahead.